InnoTherapy Obtains Patent Rights for Stabilization Related to Adeno-Associated Virus
[Asia Economy Reporter Oh Ju-yeon] InnoTherapy announced on the 14th that it has obtained a domestic patent for a stabilizer for adeno-associated virus and a method for stabilizing adeno-associated virus using the same.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Wallets Open Wide on Big News...300 Trillion Won Heads to the U.S., "Tax Breaks" Fail to Keep Funds at Home
- "Realizing How Fast Money Disappears: Should You Try Only the Essentials for 5,000 Won? [The Basics of Benefits]"
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
The company stated, "Adeno-associated virus, which is attracting attention as an efficient delivery vehicle for gene therapy, has excellent safety but faces stability limitations due to excessive aggregation during the manufacturing process. This technology can maintain adeno-associated virus particles in a state effective for drug delivery, thereby enhancing stability. We plan to utilize it in gene therapy development and drug delivery technology."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
